Session I: Immunity Beyond T cells
2–3:20 p.m. EST
|
2 p.m.
|
Welcome: Unleashing Curiousity, Courage and Conviction for The Next Wave of Immunotherapy
Zhen Su, MD, MBA – Marengo Therapeutics
|
| 2:10 p.m. |
Beyond the Horizon. How Targeting Myeloid cells can Revolutionize Cancer Immunotherapy
Dmitry I. Gabrilovich, MD, PhD – AstraZeneca
|
| 2:30 p.m. |
Leveraging B-cell Immunity to Promote PD-1 blockade Effectiveness in Glioblastoma
David Hou – Northwestern University
|
| 2:40 p.m. |
A Combined Strategy of CD70 CAR Co-expression with Membrane-bound IL-15 and CISH Knockout Results in Enhanced NK Cytotoxicity and Persistence
James B. Trager, PhD – Nkarta Therapeutics
|
| 2:50 p.m. |
Panel Discussion
Moderator: Francesco M. Marincola, MD – Kite, A Gilead Company
Panelists: Dmitry I. Gabrilovich, MD, PhD – AstraZeneca
David Hou – Northwestern University
Katy Rezvani, MD, PhD – MD Anderson Cancer Center
James B. Trager, PhD – Nkarta Therapeutics
|
Session II: CAR T and other Cell Therapies in Solid Tumors
3:20–4:30 p.m. EST
|
| 3:20 p.m. |
Equipping CAR T for Solid Tumors: Challenges and Opportunities
Carl H. June, MD – University of Pennsylvania
|
| 3:40 p.m. |
Secretion of Matrix Metallopeptidase 8 Promotes Tumor Infiltration and Antitumor Activity of CAR T cells
Irfan N. Bandey, PhD – University of Houston
|
| 3:50 p.m. |
AlloCAR TTM Cells Built for Enhanced Expansion, Persistence, and the Ability to Overcome the Solid Tumor Microenvironment
Barbra J. Sasu, PhD – Allogene Therapeutics
|
| 4:00 p.m. |
Debate/Panel Discussion
Moderator: Kald Abdallah, MD, PhD – Bristol Myers Squibb
Panelists: Irfan N. Bandey, PhD – University of Houston
Carl H. June, MD – University of Pennsylvania
Marcela V. Maus, MD, PhD – Massachusetts General Hospital
Barbra J. Sasu, PhD – Allogene Therapeutics
|
| 4:30 p.m. |
Break
|
Session III: Novel Combinations
4:45–6:00 p.m. EST
|
| 4:45 p.m. |
The Evolving Landscape of Immunotherapy Combinations
Jonathan Cheng, MD – Bristol Myers Squibb
|
| 5:05 p.m. |
Beyond T cells and Bispecific Antibodies for Solid Tumors: Odyssey of Bispecific Antibody (BiAb) Armed Activated T cells (BATs)
Lawrence G. Lum, MD, DSc – University of Virginia
|
| 5:15 p.m. |
INO-5401 and INO-9012 Delivered Intramuscularly (IM) with Electroporation (EP) in Combination with Cemiplimab (REGN2810) in Newly Diagnosed Glioblastoma
David A. Reardon, MD – Dana-Farber Cancer Institute
|
| 5:25 p.m. |
Panel Discussion
Moderator: Giovanni Melillo, MD – AstraZeneca
Panelists: Jonathan Cheng, MD – Bristol Myers Squibb
Sandra Demaria, MD – Weill Cornell Medicine
Lawrence G. Lum, MD, DSc – University of Virginia
David A. Reardon, MD – Dana-Farber Cancer Institute
|
| 5:55 p.m. |
Closing Remarks
Kald Abdallah, MD, PhD – Bristol Myers Squibb
|
|
|